President Trump’s recent executive order on pharmaceuticals has brought attention to the potential for more prescription drugs to be switched to over-the-counter status. This move aims to accelerate the pace of switches, particularly in therapeutic areas that have not seen reclassifications in the past. However, without clear strategies to encourage novel switches, obstacles to expanding OTC options may persist.
In 2023, two significant switches occurred – the contraceptive norgestrel and the opioid antidote naloxone. However, there were no recorded switches by the FDA in 2024. Prior to 2023, most switches were in therapeutic areas like acne, heartburn, pain, and allergies, where OTC alternatives already existed. This trend highlights the need for more innovative approaches to drive switches in categories with limited OTC options.
President Trump’s executive order, titled Lowering Drug Prices by Once Again Putting Americans First, includes a focus on improving the process for transitioning prescription drugs to OTC medications. While this goal aligns with the desire for more novel switches, the order lacks specific strategies for implementation. Additionally, recent FDA layoffs may hinder the agency’s ability to act on potential switch opportunities.
The administration’s handling of a rule intended to facilitate more reclassifications has also raised concerns. The effective date of a Biden administration rule, which would expand the range of prescription drugs eligible for OTC status, has been delayed twice. This rule would introduce an “additional condition for nonprescription use” protocol, requiring consumers to demonstrate understanding of a product’s instructions before purchase.
The process of switching prescription drugs to OTC status typically involves safety and effectiveness studies, as well as label comprehension assessments. While the U.S. has a binary system of Rx or OTC products, other countries like the UK have a formal “pharmacy” category for behind-the-counter products. This system allows for pharmacist consultation before purchasing certain medications, such as low-dose statins and erectile dysfunction drugs.
Despite efforts to reform the reclassification system in the U.S., novel switches in therapeutic classes like high cholesterol, erectile dysfunction, and migraine remain elusive. The introduction of initiatives like the NSURE program in 2013 aimed to spur new switches, but progress has been limited. To facilitate more novel switches, there may be a need for behind-the-counter alternatives that involve pharmacist consultations or protocols for adding conditions for nonprescription use.
In conclusion, the push for more OTC switches presents an opportunity to expand access to medications and lower healthcare costs. By addressing barriers to novel switches and implementing clear strategies for reclassification, the U.S. healthcare system can enhance consumer choice and promote better health outcomes.
